Illuminating Small Molecule Oral Agonists in the Clinic to Redefine a New Paradigm in Obesity

Time: 8:30 am
day: Day One


  • Weight loss, diabetes remission and cardiovascular improvements in a pill: reformulating a potent small molecule GLP-1 RA in the clinic
  • Investigating the current state of play in developing oral incretins
  • Delineating clinical breakthroughs in obesity and T2D drug development to define the unmet medical need and inform the next steps in drug development